Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease

A biomarker, inflammatory joint technology, applied in biological testing, biological material analysis, antibodies, etc., can solve problems such as not seen
CN101932935AInactive Publication Date: 2010-12-29MERCK & CO INC
29 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
MERCK & CO INC
Publication Date
2010-12-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of US Provisional Patent Application 60 / 945,239, filed June 20, 2007. field of invention

[0002] In general, the present invention relates to the treatment of inflammatory joint diseases with interleukin-17A (IL-17A) antagonists. More specifically, the present invention relates to biomarkers associated with the inhibitory efficacy of IL-17A antagonists on joint destruction in rheumatoid arthritis and related arthritic rashes. Background of the invention

[0003] Rheumatoid arthritis (RA) is an inflammatory disease caused by a dysregulation of the immune system that results in inflammation of the joints, causing joint pain, discomfort, swelling and stiffness with progressive bone and cartilage erosion. Inflammation and structural joint damage combine to cause loss of function that can lead to permanent disability.

[0004] IL-17A, formerly known as cytotoxic T lymphocyte-associated antigen 8 (CTLA8), is a homodimeric cytokine that ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More